Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (vol 23, pg 861, 2020)

被引:154
|
作者
Folegatti, Pedro M.
Bittaye, Mustapha
Flaxman, Amy
Lopez, Fernando Ramos
Bellamy, Duncan
Kupke, Alexandra
Mair, Catherine
Makinson, Rebecca
Sheridan, Jonathan
Rohde, Cornelius
Halwe, Sandro
Jeong, Yuji
Park, Young-Shin
Kim, Jae-Ouk
Song, Manki
Boyd, Amy
Nguyen Tran
Silman, Daniel
Poulton, Ian
Datoo, Mehreen
Marshall, Julia
Themistocleous, Yrene
Lawrie, Alison
Roberts, Rachel
Berrie, Eleanor
Becker, Stephan
Lambe, Teresa
Hill, Adrian
Ewer, Katie
Gilbert, Sarah
机构
[1] The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford
[2] Institute of Virology, Philipps University of Marburg, Marburg
[3] German Center for Infection Research, Thematic Translational Unit Emerging Infections, Marburg
[4] International Vaccine Institute, Science Unit, Seoul
来源
LANCET INFECTIOUS DISEASES | 2020年 / 20卷 / 07期
关键词
D O I
10.1016/S1473-3099(20)30160-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans. Methods: This dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial was done at the Centre for Clinical Vaccinology and Tropical Medicine (Oxford, UK) and included healthy people aged 18–50 years with negative pre-vaccination tests for HIV antibodies, hepatitis B surface antigen, and hepatitis C antibodies (and a negative urinary pregnancy test for women). Participants received a single intramuscular injection of ChAdOx1 MERS at three different doses: the low-dose group received 5 × 109 viral particles, the intermediate-dose group received 2·5 × 1010 viral particles, and the high-dose group received 5 × 1010 viral particles. The primary objective was to assess safety and tolerability of ChAdOx1 MERS, measured by the occurrence of solicited, unsolicited, and serious adverse events after vaccination. The secondary objective was to assess the cellular and humoral immunogenicity of ChAdOx1 MERS, measured by interferon-γ-linked enzyme-linked immunospot, ELISA, and virus neutralising assays after vaccination. Participants were followed up for up to 12 months. This study is registered with ClinicalTrials.gov, NCT03399578. Findings: Between March 14 and Aug 15, 2018, 24 participants were enrolled: six were assigned to the low-dose group, nine to the intermediate-dose group, and nine to the high-dose group. All participants were available for follow-up at 6 months, but five (one in the low-dose group, one in the intermediate-dose group, and three in the high-dose group) were lost to follow-up at 12 months. A single dose of ChAdOx1 MERS was safe at doses up to 5 × 1010 viral particles with no vaccine-related serious adverse events reported by 12 months. One serious adverse event reported was deemed to be not related to ChAdOx1 MERS. 92 (74% [95% CI 66–81]) of 124 solicited adverse events were mild, 31 (25% [18–33]) were moderate, and all were self-limiting. Unsolicited adverse events in the 28 days following vaccination considered to be possibly, probably, or definitely related to ChAdOx1 MERS were predominantly mild in nature and resolved within the follow-up period of 12 months. The proportion of moderate and severe adverse events was significantly higher in the high-dose group than in the intermediate-dose group (relative risk 5·83 [95% CI 2·11–17·42], p<0·0001) Laboratory adverse events considered to be at least possibly related to the study intervention were self-limiting and predominantly mild in severity. A significant increase from baseline in T-cell (p<0·003) and IgG (p<0·0001) responses to the MERS-CoV spike antigen was observed at all doses. Neutralising antibodies against live MERS-CoV were observed in four (44% [95% CI 19–73]) of nine participants in the high-dose group 28 days after vaccination, and 19 (79% [58–93]) of 24 participants had antibodies capable of neutralisation in a pseudotyped virus neutralisation assay. Interpretation: ChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The results of this first-in-human clinical trial support clinical development progression into field phase 1b and 2 trials. Funding: UK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research. © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
引用
收藏
页码:148 / 148
页数:1
相关论文
共 30 条
  • [11] Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
    Jenkin, Daniel
    Wright, Daniel
    Folegatti, Pedro M.
    Platt, Abigail
    Poulton, Ian
    Lawrie, Alison
    Tran, Nguyen
    Boyd, Amy
    Turner, Cheryl
    Gitonga, John N.
    Karanja, Henry K.
    Mugo, Daisy
    Ewer, Katie J.
    Bowden, Thomas A.
    Gilbert, Sarah C.
    Charleston, Bryan
    Kaleebu, Pontiano
    Hill, Adrian V. S.
    Warimwe, George M.
    LANCET INFECTIOUS DISEASES, 2023, 23 (08): : 956 - 964
  • [12] Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
    Hamer, Melinda J.
    Houser, Katherine, V
    Hofstetter, Amelia R.
    Ortega-Villa, Ana M.
    Lee, Christine
    Preston, Anne
    Augustine, Brooke
    Andrews, Charla
    Yamshchikov, Galina, V
    Hickman, Somia
    Schech, Steven
    Hutter, Jack N.
    Scott, Paul T.
    Waterman, Paige E.
    Amare, Mihret F.
    Kioko, Victoria
    Storme, Casey
    Modjarrad, Kayvon
    McCauley, Melanie D.
    Robb, Merlin L.
    Gaudinski, Martin R.
    Gordon, Ingelise J.
    Holman, LaSonji A.
    Widge, Alicia T.
    Strom, Larisa
    Happe, Myra
    Cox, Josephine H.
    Vazquez, Sandra
    Stanley, Daphne A.
    Murray, Tamar
    Dulan, Caitlyn N. M.
    Hunegnaw, Ruth
    Narpala, Sandeep R.
    Swanson II, Phillip A.
    Basappa, Manjula
    Thillainathan, Jagada
    Padilla, Marcelino
    Flach, Britta
    O'Connell, Sarah
    Trofymenko, Olga
    Morgan, Patricia
    Coates, Emily E.
    Gall, Jason G.
    McDermott, Adrian B.
    Koup, Richard A.
    Mascola, John R.
    Ploquin, Aurelie
    Sullivan, Nancy J.
    Ake, Julie A.
    Ledgerwood, Julie E.
    LANCET, 2023, 401 (10373): : 294 - 302
  • [13] Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial
    Dixit, Avika
    Bennett, Richard
    Ali, Kashif
    Griffin, Carl
    Clifford, Robert A.
    Turner, Mark
    Poston, Rosanne
    Hautzinger, Kelly
    Yeakey, Anne
    Girard, Bethany
    Zhou, Wen
    Deng, Weiping
    Zhou, Honghong
    Ghamloush, Sabine Schnyder
    Kuter, Barbara J.
    Slobod, Karen
    Miller, Jacqueline M.
    Priddy, Frances
    Das, Rituparna
    LANCET INFECTIOUS DISEASES, 2024, 24 (07): : 687 - 697
  • [14] Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
    Mwesigwa, Betty
    Houser, Katherine, V
    Hofstetter, Amelia R.
    Ortega-Villa, Ana M.
    Naluyima, Prossy
    Kiweewa, Francis
    Nakabuye, Immaculate
    Yamshchikov, Galina, V
    Andrews, Charla
    O'Callahan, Mark
    Strom, Larisa
    Schech, Steven
    Eller, Leigh Anne
    Sondergaard, Erica L.
    Scott, Paul T.
    Amare, Mihret F.
    Modjarrad, Kayvon
    Wamala, Amir
    Tindikahwa, Allan
    Musingye, Ezra
    Nanyondo, Jauhara
    Gaudinski, Martin R.
    Gordon, Ingelise J.
    Holman, LaSonji A.
    Saunders, Jamie G.
    Costner, Pamela J. M.
    Mendoza, Floreliz H.
    Happe, Myra
    Morgan, Patricia
    Plummer, Sarah H.
    Hickman, Somia P.
    Vazquez, Sandra
    Murray, Tamar
    Cordon, Jamilet
    Dulan, Caitlyn N. M.
    Hunegnaw, Ruth
    Basappa, Manjula
    Padilla, Marcelino
    Gajjala, Suprabhath R.
    Swanson II, Phillip A.
    Lin, Bob C.
    Coates, Emily E.
    Gall, Jason G.
    McDermott, Adrian B.
    Koup, Richard A.
    Mascola, John R.
    Ploquin, Aurelie
    Sullivan, Nancy J.
    Kibuuka, Hannah
    Ake, Julie A.
    LANCET INFECTIOUS DISEASES, 2023, 23 (12): : 1408 - 1417
  • [15] Safety and immunogenicity of an HIV-1 prefusion- stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label , randomized, dose-escalation, phase 1 clinical trial
    Houser, Katherine, V
    Gaudinski, Martin R.
    Happe, Myra
    Narpala, Sandeep
    Verardi, Raffaello
    Sarfo, Edward K.
    Corrigan, Angela R.
    Wu, Richard
    Rothwell, Ro Shauna
    Novik, Laura
    Hendel, Cynthia S.
    Gordon, Ingelise J.
    Berkowitz, Nina M.
    Cartagena, Cora Trelles
    Widge, Alicia T.
    Coates, Emily E.
    Strom, Larisa
    Hickman, Somia
    Conan-Cibotti, Michelle
    Vazquez, Sandra
    Trofymenko, Olga
    Plummer, Sarah
    Stein, Judy
    Case, Christopher L.
    Nason, Martha
    Biju, Andrea
    Parchment, Danealle K.
    Changela, Anita
    Cheng, Cheng
    Duan, Hongying
    Geng, Hui
    Teng, I-Ting
    Zhou, Tongqing
    O'Connell, Sarah
    Barry, Chris
    Carlton, Kevin
    Gall, Jason G.
    Flach, Britta
    Doria-Rose, Nicole A.
    Graham, Barney S.
    Koup, Richard A.
    McDermott, Adrian B.
    Mascola, John R.
    Kwong, Peter D.
    Ledgerwood, Julie E.
    ECLINICALMEDICINE, 2022, 48
  • [16] Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK
    Borthwick, Nicola
    Fernandez, Natalia
    Hayes, Peter J.
    Wee, Edmund G. -T
    Yildirim, Belkis M. Akis
    Baines, Andrea
    Baker, Megan
    Byard, Nicholas
    Conway, Oliver
    Glaze, Molly
    Jenkin, Daniel
    Larkworthy, Colin
    Luciw, Michael
    Platt, Abigail
    Poulton, Ian
    Thomas, Merin
    Quaddy, Jack
    Watson, Marion
    Crook, Alison
    Cicconir, Paola
    Hanker, Tomas
    LANCET MICROBE, 2025, 6 (03):
  • [17] Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo- controlled phase 2 trial
    Gorman, Ellen
    Shankar-Hari, Manu
    Hopkins, Phil
    Tunnicliffe, William S.
    Perkins, Gavin D.
    Silversides, Jonathan
    McGuigan, Peter
    Jackson, Colette
    Boyle, Roisin
    McFerran, Jamie
    McDowell, Cliona
    Campbell, Christina
    McFarland, Margaret
    Smythe, Jon
    Thompson, Jacqui
    Williams, Barry
    Curley, Gerard
    Laffey, John G.
    Clarke, Mike
    McAuley, Daniel F.
    O'Kane, Cecilia
    TRIALS, 2022, 23 (01)
  • [18] Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial
    Ellen Gorman
    Manu Shankar-Hari
    Phil Hopkins
    William S. Tunnicliffe
    Gavin D. Perkins
    Jonathan Silversides
    Peter McGuigan
    Colette Jackson
    Roisin Boyle
    Jamie McFerran
    Cliona McDowell
    Christina Campbell
    Margaret McFarland
    Jon Smythe
    Jacqui Thompson
    Barry Williams
    Gerard Curley
    John G. Laffey
    Mike Clarke
    Daniel F. McAuley
    Cecilia O’Kane
    Trials, 23
  • [19] Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial
    Manno, Daniela
    Bangura, Agnes
    Baiden, Frank
    Kamara, Abu Bakarr
    Ayieko, Philip
    Kallon, Joseph
    Foster, Julie
    Conteh, Musa
    Connor, Nicholas Edward
    Koroma, Bockarie
    Njie, Yusupha
    Borboh, Paul
    Keshinro, Babajide
    Lawal, Bolarinde Joseph
    Kroma, Mattu Tehtor
    Otieno, Godfrey Tuda
    Deen, Abdul Tejan
    Choi, Edward Man-Lik
    Balami, Ahmed Dahiru
    Gaddah, Auguste
    McLean, Chelsea
    Luhn, Kerstin
    Adetola, Hammed Hassan
    Deen, Gibrilla Fadlu
    Samai, Mohamed
    Lowe, Brett
    Robinson, Cynthia
    Leigh, Bailah
    Greenwood, Brian
    Watson-Jones, Deborah
    LANCET INFECTIOUS DISEASES, 2023, 23 (03): : 352 - 360
  • [20] Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17years in China: a randomised, double-blind, placebo- controlled, phase 1trial and an open-label, non-randomised, non-inferiority, phase 2 trial
    Gao, Lidong
    Li, Yan
    He, Peng
    Chen, Zhen
    Yang, Huaiyu
    Li, Fangjun
    Zhang, Siyuan
    Wang, Danni
    Wang, Guangyan
    Yang, Shilong
    Gong, Lihui
    Ding, Fan
    Ling, Mengyu
    Wang, Xilu
    Ci, Leilei
    Dai, Lianpan
    Gao, George Fu
    Huang, Tao
    Hu, Zhongyu
    Ying, Zhifang
    Sun, Jiufeng
    Zuo, Xiaohu
    LANCET CHILD & ADOLESCENT HEALTH, 2023, 7 (04): : 269 - 279